Creative Biolabs supports pre-clinical in vitro immunological analysis of vaccines. We provide complete immunogenicity assessment of vaccine products, immunotoxicity assessment, coverage immunoassays, and cell-based cellular immune functional assays in GLP-certified laboratories.
Our vaccine solutions also include analytics development, efficacy monitoring, project management, and data management to meet your development needs throughout the vaccine development life cycle. We can work with you to develop and validate customized assays to meet your drug development goals.
Immunogenicity refers to the ability of an antigen to induce an immune response. Creative Biolabs has the expertise and resources to develop and validate methods and perform sample analysis to help you fully understand the discovery of vaccine products and pre-clinical immunogenicity.
Creative Biolabs immunology team provides you with a fully integrated service to assess the potential of vaccines as immunosuppressants or immunostimulants and to determine immunological endpoints and antigen-induced changes in cell function.
Creative Biolabs is able to predict potential immunotoxicology during pre-clinical development. By working with you and understanding your goals, we can tailor testing methods to suit your needs. Our analysis uses whole blood and PBMC, but also uses purified populations (e.g., T cells, dendritic cells, macrophages, platelets, and endothelial cells) that allow us to monitor functional changes.
For more details, please feel free to contact us for project quotations and more detailed information.
For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
End-to-end CAR Hybrid TCR (CHyT)-T Cell Therapy Development Services: A novel solution to engineer T cell to be a promising cellular therapy with the complete TCR without HLA dependence.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE